Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001104659-19-062602
Filing Date
2019-11-12
Accepted
2019-11-12 16:03:47
Documents
48
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 6-K a19-22440_16k.htm 6-K 18339
2 EX-99.1 a19-22440_1ex99d1.htm EX-99.1 444282
3 EX-99.2 a19-22440_1ex99d2.htm EX-99.2 393810
  Complete submission text file 0001104659-19-062602.txt   2404643

Data Files

Seq Description Document Type Size
4 EX-101.INS prqr-20190930.xml EX-101.INS 256365
5 EX-101.SCH prqr-20190930.xsd EX-101.SCH 35846
6 EX-101.CAL prqr-20190930_cal.xml EX-101.CAL 32704
7 EX-101.DEF prqr-20190930_def.xml EX-101.DEF 61665
8 EX-101.LAB prqr-20190930_lab.xml EX-101.LAB 240431
9 EX-101.PRE prqr-20190930_pre.xml EX-101.PRE 153522
Mailing Address DARWINWEG 24 LEIDEN P7 2333CR
Business Address DARWINWEG 24 LEIDEN P7 2333CR 31(0)88 166 7000
ProQR Therapeutics N.V. (Filer) CIK: 0001612940 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36622 | Film No.: 191209233
SIC: 2834 Pharmaceutical Preparations